{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:23:50Z","timestamp":1792027430173,"version":"4.4.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.ophtha.2016.04.056","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T03:31:08Z","timestamp":1474428668000},"page":"S78-S88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"special_numbering":"S","title":["Anti\u2013Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease"],"prefix":"10.1016","volume":"123","author":[{"given":"Peter A.","family":"Campochiaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd Paul","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Rosenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2016.04.056_bib1","first-page":"137","article-title":"The mode of development of the vascular system of the retina with some observations on its significance for certain retinal diseases","volume":"68","author":"Michaelson","year":"1948","journal-title":"Trans Ophthalmol Soc UK"},{"key":"10.1016\/j.ophtha.2016.04.056_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0002-9394(57)90426-9","article-title":"Retinal vascularization in health and disease","volume":"44","author":"Ashton","year":"1957","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib3","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1021\/bi00348a001","article-title":"Retina- and eye-derived endothelial cell growth factors: partial molecular characterization and identity with acidic and basic fibroblast growth factors","volume":"24","author":"Baird","year":"1985","journal-title":"Biochemistry"},{"key":"10.1016\/j.ophtha.2016.04.056_bib4","doi-asserted-by":"crossref","first-page":"7297","DOI":"10.1073\/pnas.83.19.7297","article-title":"Basic fibroblast growth factor induces angiogenesis in vitro","volume":"83","author":"Montesano","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2016.04.056_bib5","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0002-9440(10)65753-7","article-title":"Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model","volume":"153","author":"Tobe","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2016.04.056_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2016.04.056_bib8","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vacular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.ophtha.2016.04.056_bib9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/359845a0","article-title":"Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo","volume":"359","author":"Plate","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2016.04.056_bib10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2016.04.056_bib11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","article-title":"Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders","volume":"331","author":"Aiello","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib12","first-page":"574","article-title":"Vascular endothelial growth factor\/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model","volume":"145","author":"Miller","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib13","first-page":"101","article-title":"Oxygen-induced retinopathy in the mouse","volume":"35","author":"Smith","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.04.056_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2016.04.056_bib15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","article-title":"Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity","volume":"1","author":"Alon","year":"1995","journal-title":"Nature Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib16","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in\u00a0vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2016.04.056_bib17","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","article-title":"Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate","volume":"114","author":"Tolentino","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib18","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","article-title":"Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate","volume":"103","author":"Tolentino","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib19","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1006\/exer.1996.0239","article-title":"Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates","volume":"64","author":"Ozaki","year":"1997","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2016.04.056_bib20","first-page":"281","article-title":"Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization","volume":"151","author":"Okamoto","year":"1997","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib21","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1001\/archopht.1982.01030040784015","article-title":"Subretinal neovascularization: natural history of an experimental model","volume":"100","author":"Ryan","year":"1982","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1001\/archopht.1989.01070010270035","article-title":"A\u00a0new model of choroidal neovascularization in the rat","volume":"107","author":"Dobi","year":"1989","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib23","first-page":"3158","article-title":"VEGF is an important stimulator in a model of choroidal neovascularization","volume":"41","author":"Kwak","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.04.056_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archopht.120.3.338","article-title":"Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment","volume":"120","author":"Kryzstolik","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/jcp.10246","article-title":"VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier","volume":"195","author":"Saishin","year":"2003","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib26","first-page":"182","article-title":"Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression","volume":"40","author":"Ozaki","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.04.056_bib27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1152\/jappl.2000.88.4.1474","article-title":"HIF-1: mediator of physiological and pathophysiological responses to hypoxia","volume":"88","author":"Semenza","year":"2000","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2016.04.056_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/jcp.20525","article-title":"Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development","volume":"206","author":"Vinores","year":"2006","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib30","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1096\/fj.04-2209fje","article-title":"Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive","volume":"19","author":"Oshima","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.ophtha.2016.04.056_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ophtha.2016.04.056_bib32","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib33","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration","volume":"112","author":"Michels","year":"2005","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib34","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.ophtha.2006.05.070","article-title":"Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Twenty-four-week results of an uncontrolled open-label clinical study","volume":"113","author":"Moshfeghi","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ajo.2007.09.025","article-title":"Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration","volume":"145","author":"Nguyen","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","article-title":"Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen","volume":"293","author":"Chen","year":"1999","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","article-title":"Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy","volume":"333","author":"Ferrara","year":"2005","journal-title":"Biochm Biophys Res Commun"},{"key":"10.1016\/j.ophtha.2016.04.056_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","article-title":"Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"36","author":"Rosenfeld","year":"2005","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2016.04.056_bib39","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib40","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib41","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib42","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. One year findings from the IVAN randomized trial","volume":"119","author":"The Ivan Study Investigators","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib43","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","article-title":"Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol","volume":"122","author":"Berg","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib44","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2016.04.056_bib45","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A\u00a0variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of PrONTO Study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","article-title":"Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol: two-year results","volume":"123","author":"Berg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib49","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib50","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2014.09.012","article-title":"Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes","volume":"159","author":"Channa","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib52","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ophtha.2014.07.046","article-title":"Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration","volume":"122","author":"Tanaka","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib53","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib54","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib55","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","article-title":"EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy","volume":"32","author":"Koh","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.04.056_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1167\/iovs.03-0557","article-title":"Supplemental inspired oxygen improves diabetic macular edema: a pilot study","volume":"45","author":"Nguyen","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.04.056_bib57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0002-9440(10)64773-6","article-title":"Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization","volume":"156","author":"Ozaki","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib58","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1167\/iovs.03-0955","article-title":"Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412","volume":"45","author":"Campochiaro","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2016.04.056_bib59","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajo.2006.06.068","article-title":"Vascular endothelial growth factor is a critical stimulus for diabetic macular edema","volume":"142","author":"Nguyen","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib60","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ophtha.2009.04.023","article-title":"Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study","volume":"116","author":"Nguyen","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib61","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"The Diabetic Retinopathy Clinical Research Network","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib62","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema. Results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib63","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib64","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2016.04.056_bib65","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib66","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","article-title":"Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy","volume":"118","author":"Adamis","year":"1994","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib67","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1755-3768.2008.01391.x","article-title":"Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib","volume":"87","author":"Mendrinos","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib68","doi-asserted-by":"crossref","first-page":"1695.e1","DOI":"10.1016\/j.ophtha.2006.05.064","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib69","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/IAE.0b013e3181bf5ff0","article-title":"The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy","volume":"30","author":"Erdol","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2016.04.056_bib70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/112067210801800215","article-title":"Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial","volume":"18","author":"Mirshahi","year":"2008","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1600-0420.2007.01056.x","article-title":"Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study)","volume":"86","author":"Tonello","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib72","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Writing Committee for the Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ophtha.2016.04.056_bib73","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1001\/archophthalmol.2012.1043","article-title":"Long-term effects of ranibizumab on diabetic retinopathy severity and progression","volume":"130","author":"Ip","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib74","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jamaophthalmol.2013.4154","article-title":"Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial","volume":"131","author":"Bressler","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib75","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ophtha.2014.03.021","article-title":"Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib76","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archopht.1996.01100130062010","article-title":"Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization","volume":"114","author":"Adamis","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.ophtha.2016.04.056_bib78","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib79","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion: 6-month results of the phase III CRUISE study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib80","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/j.ophtha.2011.02.038","article-title":"Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib81","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ophtha.2011.02.022","article-title":"Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study","volume":"118","author":"Brown","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib82","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.ophtha.2012.01.042","article-title":"Vascular endothelial growth factor trap-eye for macular edema secondary to central retinal vein occlusion. Six-month results of the phase 3 COPERNICUS study","volume":"119","author":"Boyer","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib83","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ajo.2012.09.026","article-title":"Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study","volume":"155","author":"Brown","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib84","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/bjophthalmol-2012-301504","article-title":"VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study","volume":"97","author":"Holz","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib85","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ophtha.2013.08.012","article-title":"Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion. One-year results of the phase 3 GALILEO study","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib86","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.ophtha.2012.01.022","article-title":"Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study","volume":"119","author":"Epstein","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib87","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ajo.2013.05.039","article-title":"Long term outcomes in ranibizumab-treated patients with retinal vein occlusion: the role of progression of retinal nonperfusion","volume":"156","author":"Sophie","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib88","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN Study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ophtha.2012.09.032","article-title":"Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion","volume":"120","author":"Campochiaro","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib90","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ophtha.2015.10.030","article-title":"Changes in retinal nonperfusion associated with suppression of vascular endothelial growth factor in retinal vein occlusion","volume":"123","author":"Mir","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2016.04.056_bib91","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2016.04.056_bib92","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/eye.2014.94","article-title":"Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema","volume":"28","author":"Hanhart","year":"2014","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2016.04.056_bib93","first-page":"CD007419","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema","volume":"10","author":"Virgili","year":"2014","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016302767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642016302767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T16:42:11Z","timestamp":1568392931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642016302767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0161642016302767"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.056","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti\u2013Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2016.04.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}